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REVIEW
Incorporating health inequality impact into economic evaluation in low- and 
middle-income countries: a systematic review
Fan Yanga, Kenneth Roger Katumbab and Susan Griffina
aCentre for Health Economics, University of York, York, UK; bMRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda
ABSTRACT
Introduction: As well as improving population health, promoting equity in health is one of the key 
goals of health policy in low- and middle-income countries (LMICs). However, it is less clear how equity 
is defined, or how it may impact on resource allocation decisions. We investigated the degree to which 
health inequalities have been considered in economic evaluation of health interventions in LMICs, and 
what demographic or socioeconomic characteristics were used to define equity relevant subgroups.
Areas covered: We reviewed publications since 2010 from three main databases following the search 
strategy developed by including the key terms ‘health inequalities/health disparities/health equity,’ 
‘economics’ and ‘low- and middle-income countries’ in the title or abstract. Twelve studies were 
identified, mainly focusing on interventions for the more vulnerable groups such as children and 
women.
Expert opinion: Some attempts have been made to assess interventions’ impact on health inequality 
and there is increasing interest in evaluating it, although research in this area is lacking. Population 
subgroups highlighted in the included studies were those differing in socioeconomic status. Most 
studies reported the results across subgroups to illustrate inequality impact, and the newly developed 
methods, extended cost-effectiveness analysis and distributional cost-effectiveness analysis, have also 
been applied.
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1. Introduction
The past three decades have witnessed significant progress in 
improving the health of people in low- and middle-income 
countries (LMICs) such as reduced child mortality and 
increased life expectancy [1]. Empirical studies of the differ-
ences in health between the poor and the better off found 
that the gap has remained appreciable, with the poor facing 
lower odds of receiving key health interventions and worse 
health outcomes [2,3]. As well as improving population health, 
promoting equity in health is one of the key goals of health 
policy in LMICs [4–7].
Health equity includes equal access to healthcare services 
and fair health outcomes among population groups defined 
socially, economically, demographically or geographically. An 
increasing number of LMICs are currently offering or striving 
for universal healthcare coverage, aiming to provide equal 
care to all, but access to these services is still unequal, evi-
denced by the literature that explored the differences in 
access to healthcare in LMICs [8–11]. The unfair health out-
comes that are considered avoidable are referred to as ‘health 
inequality.’ This means poorer health, reduced health-related 
quality of life (HRQoL) and early death for the more disadvan-
taged people. Reducing these inequalities is a key feature of 
global health policy agendas, contributing to the sustainable 
development goals [12,13]. Economic evaluation methods, 
such as cost-effectiveness analysis (CEA), have been widely 
used to inform healthcare resource allocation decisions, but 
mainly focus on how the intervention or policy affects total 
health [14]. Recent methodological developments have 
included health inequality concerns into economic evaluation 
to describe the distribution of health benefits, for example the 
extended cost-effectiveness analysis (ECEA) [15], which pro-
vides breakdowns of health outcomes, out of pocket expen-
diture and financial risk protection by population group, and 
distributional cost-effectiveness analysis (DCEA) [16], which 
focuses on the breakdown of health outcomes and opportu-
nity costs, and provides summary measures of health inequal-
ity impact to inform potential trade-offs between increasing 
overall health and reducing health inequality.
More studies are applying the newly developed methods, 
ECEA or DCEA, in LMICs, such as in India [15], Ethiopia [17] and 
Malawi [18]. We sought to develop an overview of the extent 
to which inequality impact has been considered in economic 
evaluations of health interventions or policies in LMICs before 
and after these methods became more widely known. We 
summarize what approaches have been used to describe the 
distribution or the different impact across the population 
groups, and what equity relevant groups were considered in 
the evaluation and what demographic or socioeconomic char-
acteristics were used to characterize these groups.
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Thus, through a systematic review, we would like to inform 
the following questions:
1. has the inequality impact been included in economic 
evaluation in LMICs?
2. what equity relevant groups were considered?
3. what approaches have been used to assess the impact?
2. Methods
The systematic review was conducted and reported following 
the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statement [19].
2.1. Search strategy
Three databases were searched: Ovid MEDLINE (1946 to 
1 February 2021), Ovid EMBASE (1974 to 1 February 2021) 
and Global Health Cost-Effectiveness Analysis Registry 
(publication year: 1995 to 2020) (http://ghcearegistry.org/ 
ghcearegistry/). All searches were conducted on 
2 February 2021. The search strategy was developed by 
including the key terms ‘health inequalities/health dispa-
rities/health equity,’ ‘economics’ and ‘low- and middle- 
income countries’ and their synonyms in the title or 
abstract. We did not use the terms ‘economic evaluation’ 
or ‘cost-effectiveness analysis’ because a lot of commis-
sioned studies for LMICs were cost-benefit analyses and 
social returns on investment, which may not be captured 
using this narrower strategy. A detailed search strategy is 
available in Appendix 1.
2.2. Eligibility criteria
After dropping duplicates, two reviewers independently 
screened the titles and abstracts of all the records identified 
from the database searches using the inclusion criteria 
detailed below.
● Peer-reviewed journal articles, reports published by non- 
government organizations (NGOs) or health technology 
assessment (HTA) bodies, studies published in discussion 
papers by academic institutions.
● Studies focused on the populations in LMICs, studies 
featuring multinational participants including LMICs and 
it is possible to isolate the results for these participants 
from LMICs.
● Economic evaluation studies in which the health out-
comes were reported or estimated.
● Studies with a focus on health inequality in which the 
different health outcomes across population groups 
were assessed or discussed. The population groups 
should be defined based on non-clinical characteris-
tics, e.g. ethnicity, sex, education.
● Publications in the last 10 years (since 2010)
All other publication types, including conference abstracts, 
study protocols, commentaries, editorials, were excluded. 
The list of countries with low-income or middle-income 
economies compiled by the Organization for Economic Co- 
operation and Development was used [20]. Reviews of 
prior studies were excluded, but references in review arti-
cles were screened to identify additional original studies 
missed by the search strategy. Studies including popula-
tion groups defined by clinical characteristics, e.g. low-risk 
and high-risk, were excluded as the differences in health 
outcomes may not be avoidable.
After the screening of titles and abstracts, the two 
reviewers independently reviewed the full-text of any arti-
cle that appeared to meet the eligibility criteria to reach 
a consensus on the final list of included studies. Any dis-
crepancy in the reviewing process was resolved by discus-
sion between the two reviewers and by consulting with 
a third reviewer if necessary.
The quality of included full-text studies was assessed 
using the International Society for Pharmacoeconomics 
and Outcomes Research (ISPOR) Consolidated Health 
Economic Evaluation Reporting Standards (CHEERS) 24- 
item checklist [21].
2.3. Data extraction
Upon agreement on the final list of included studies, one 
reviewer extracted data from the included studies into 
a predefined Microsoft Excel form. Subsequently, another 
author validated the extracted data by checking them. The 
form was developed following the reporting guidelines for 
systematic reviews with a focus on health equity [22], 
including information about authors, year of publication, 
country, target population, intervention, comparator, type 
of study, costs perspective, health outcomes, modeling, 
population subgroups, method, and main results 
(Appendix 2). Followed the PROGRESS-Plus criteria [23], 
characteristics used in the included studies to characterize 
population subgroups related to equity were collected 
including place of residence, race/ethnicity/culture/lan-
guage, occupation, gender/sex, religion, education, socio-
economic status, social capital and other associated 
characteristics (e.g. age, disability, excluded from school, 
Article highlights 
● In low- and middle-income countries, the impact on health inequality 
has been considered in economic evaluation of health interventions.
● The evaluation studies mainly focused on interventions for the more 
vulnerable groups such as children and women.
● There is an increasing trend to consider inequality impact to inform 
public health policy makers.
● Population subgroups characterized by socioeconomic status are 
most associated with of resource allocation and prioritization 
decisions.
● Most studies reported the results across subgroups to illustrate 
inequality impact, and some studies have also applied the ECEA or 
DCEA method.
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other instances where a person may be temporarily at 
a disadvantage).
3. Results
3.1. Characteristics of the studies
The search identified a total of 1742 records. After dropping 
duplicates, non-peered reviewed articles and publications 
before 2010, 796 records were screened for titles and abstracts 
and 36 were further screened for full-text. Finally, 12 studies 
met the inclusion criteria and were included in the systematic 
review (see Figure 1, PRISMA diagram). Table 1 summarizes 
the characteristics of all included studies.
Majority of the included studies (ten studies, 83.3%) were 
CEA, using Markov model [24–26], dynamic transmission 
model [15] or microsimulation [27]. In the two studies which 
were not CEA [28,29], economic evaluations were conducted 
with health outcomes, but they did not report results on costs; 
both studies were included to extract the method used to 
estimate inequality impact. Mortality was most commonly 
included as main health outcome [15,17,24,26,28–32]; generic 
metrics such as life years [26–28], disability-adjusted life years 
(DALYs) [18,25,28,30–32], quality-adjusted life years (QALYs) 
[24] and health-adjusted life years (HALYs) [17], and other 
disease-specific outcomes, e.g. hepatitis B infections averted 
[24], cervical cancer cases averted [27] and obesity prevalence 
[28], were also included as health outcomes.
Quality of the included ten CEA studies was assessed and 
the total and individual CHEERs checklist scores are presented 
in Figure 2 and Tables S1-S2. In general, there was good 
adherence to best-practice reporting standards, with ‘satisfied’ 
or ‘partially satisfied’ in almost all the 24 items. It should be 
noted that among the 10 CEA studies, one study did not 
report results of uncertainty analysis [26]; two studies con-
ducted uncertainty analysis for the overall cost-effectiveness, 
rather than the impact on inequality [24,27]; two studies per-
formed the uncertainty analysis to a range of assumptions 
[17,18]; four studies analyzed the uncertainty about the dis-
tribution of health benefits to support inequality impact 
assessment [15,30–32]; only one studies carried out full uncer-
tainty analysis (including probabilistic sensitivity analysis) for 
the inequality impact and provided the confidence level of the 
conclusion about whether the intervention increases/reduces 
health inequality [25].
3.2. Has the inequality impact been included in 
economic evaluation in LMICs?
As shown in Table 1, eight of the twelve included studies were 
published in the last three years (2018 onwards). This reflects 
an increasing focus on the impact, although only a few studies 
have attempted to assess the impact on health inequality.
Five studies (41.7%) assessed the impact in countries in 
Asia (China [24], India [15,30], Pakistan [31] and Laos [32]), 
five studies (41.7%) in Africa (Uganda [27], Ethiopia [17,26], 
Zambia [28], and Malawi [18]), one study (8.3%) in South 
America (Brazil [25]), and one study (8.3%) evaluated the 
results in 41 LMICs [29]. The studies were conducted in 
Figure 1. PRISMA study selection flow diagram.
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Table 1. Summary of the included studies.
Authors
Year of 
publication Country Target population Intervention Comparator
Type 
of 
study Health outcomes Modeling
Hutton et al. [24] 2010 China Children aged 1– 
19 years
Nationwide hepatitis 
B vaccination (HBV) 
program
Status quo CEA Mortality, QALYs, HBV 
infections averted
Markov
Rheingans et al. [30] 2014 India Children during the 
first 5 years of life
Rotavirus vaccination Status quo CEA Mortality, DALYs Included, but 
not detailed
Verguet et al. [15] 2015 India People with 
tuberculosis
Universal public finance 
of tuberculosis 
treatment
Status quo CEA Lives saved Dynamic 
transmission 
model
Campos et al. [27] 2017 Uganda Women aged 30– 
49 years
Cervical cancer screening 
strategies




Rheingans et al. [31] 2018 Pakistan Children during the 
first 5 years of life
Rotavirus vaccination Status quo CEA Mortality, DALYs Included, but 
not detailed
Rheingans et al. [32] 2018 Laos Children during the 
first 5 years of life
Rotavirus vaccination Status quo CEA Mortality, DALYs Included, but 
not detailed
Dawkins et al. [17] 2018 Ethiopia Children during the 




Status quo CEA Mortality, HALYs Included, but 
not detailed
Chang et al. [29] 2018 41 
LMICs
Cohorts vaccinated in 
the period 2016– 
2030
Vaccines for ten antigens1 Status quo Other Mortality Included, but 
not detailed










Arnold et al. [18] 2020 Malawi Recipients of Essential 
Health Package 
(EHP)
Essential Health Package 
(EHP)
Status quo CEA DALYs Not included
Love-Koh et al. [25] 2021 Brazil General population Community level primary 
care system 
intervention
Status quo CEA DALYs Markov
Olsen et al. [26] 2021 Ethiopia Birth cohort Children pneumonia 
treatment scale-up 
strategies
Status quo CEA Mortality, life years Markov
1measles, hepatitis B, human papillomavirus, yellow fever, Hemophilus influenzae type b, Streptococcus pneumoniae, rotavirus, rubella, Neisseria meningitidis 
serogroup A, and Japanese encephalitis. 
Figure 2. Methodological quality of the nine CEA studies for the listed in the Consolidated Health Economic Evaluation Reporting Standards (CHEERs) checklist.
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a wide variety of countries, nevertheless, concentrated in Asia 
and Africa. It implies that resource allocation and prioritization 
decisions in these countries may be informed by evidence on 
how the potential health intervention or strategy would affect 
health inequality.
Regarding the target populations and interventions or stra-
tegies assessed, more than half of the included studies (n = 7, 
58.3%) focused on children or infants [17,24,26,29–32], asses-
sing the impact of vaccination programs, e.g. nationwide 
hepatitis B vaccination [24], rotavirus vaccination [30–32] and 
vaccines for a wide range of antigens [29], and children pneu-
monia treatment scale-up strategy [26]; three studies (25.0%) 
focused on general population or adult population, covering 
complex interventions such as excise tax on sugar sweetened 
beverages [28], population level essential health package 
(EHP) [18] and community level primary care system interven-
tion [25]; one study (8.3%) focused on the impact of different 
cervical cancer screening strategies for women aged 30– 
49 years [27] and one study (8.3%) assessed the effect of 
public finance intervention for tuberculosis treatment [15].
3.3. What equity relevant groups were considered?
Table 2 presents the characteristics used in all the included 
studies to define the equity relevant population subgroups. 
Socioeconomic status was most commonly used (n = 8, 
66.7%), categorized by wealth quintiles based on household 
asset index [17,18,30–32], household income [29], an individual’s 
annual income [15] or an area-based indicator of socioeconomic 
status (gross regional product) [25]. Region was used in six 
studies, between states with different disease risks [26,30–32], 
states with different socioeconomic level [25] or urban and rural 
areas [18]. Region was used to combine with wealth quintiles to 
form more subgroups [30] or as an alternative to indicate socio-
economic status [18,25]. Sex was used in two studies [28,30] and 
other associated characteristics, e.g. age [24] and access to 
cancer screening [27], were also used.
3.4. What approaches have been used?
Table 3 presents the methods and summary of inequality 
impact used in the included studies for estimating the 
distributional effect. Six studies conducted subgroup analysis 
and reported the breakdown cost-effectiveness results to 
demonstrate the different effect across population [24,28– 
32]. One study used pre-defined outcome measures to reflect 
equity concerns [27], that is, ‘health disparity,’ which equals to 
difference in life expectancy between women with and with-
out access to cervical cancer screening, and ‘distributional 
equity,’ which equals to difference between life expectancy 
in women with access to screening and population average 
life expectancy. One study applied the Gini coefficient, 
a measure of inequality, to life expectancy to describe inter-
individual and geographical inequality impacts [26]. Four stu-
dies used the existing analysis methods, ECEA [15] or DCEA 
[17,18,25], to assess the intervention impact, but these were 
case studies, aiming to illustrate how the method can be 
applied for LMIC contexts. Among the three studies using 
DCEA, the metric for assessing inequality impact was equally 
distributed equivalence (EDE) health, a single index measure 




Economic evaluation has been increasingly used in LMICs to 
assess the ‘value for money’ of health interventions. Whilst meth-
odological advances have been made in equity-incorporated 
economic evaluation, there is still a big gap in applying these 
methods in practice in low-resource settings.
The identified studies have primarily focused on the inter-
ventions designed for improving health of the more vulner-
able groups such as rotavirus vaccination for children and 
cervical cancer screening for women. This may indicate that 
these programs are the interventions that decision makers or 
funders are most interested in understanding the inequality 
impact. Although it is well recognized that vaccines have 
contributed significantly to the improvement of population 
health in the past few decades, how different population 
groups benefit from the vaccination programs has been less 
explored. Therefore, in future studies evaluating cost- 
effectiveness of these interventions, researchers are suggested 
to consider assessing the inequality impact as well, providing 
Table 2. Characteristics used in the included studies to describe the population subgroups related to equity*.
Authors (year)
Population subgroups defined by:
Place of residence Gender/sex Socioeconomic status Others
Hutton et al. (2010) [24] Age groups
Rheingans et al. (2014) [30] Region, states Sex Wealth quintile defined by household asset index
Verguet et al. (2015) [15] Wealth quintile defined by an individual’s annual income
Campos et al. (2017) [27] Access to cervical cancer screening
Rheingans et al. (2018) [31] Region Wealth quintile defined by household asset index
Rheingans et al. (2018) [32] Region Wealth quintile defined by national asset index
Dawkins et al. (2018) [17] Household asset wealth quintile
Chang et al. (2018) [29] Household income quintile
Hangoma et al. (2019) [28] Sex
Arnold et al. (2020) [18] Urban vs rural Household wealth asset index
Love-Koh et al. (2021) [25] State A state-level indicator of socioeconomic status
Olsen et al. (2021) [26] Region
*Other items in the Progress-PLUS criteria were not shown here as they were not included in the eligible studies (race/ethnicity/ culture/language, occupation, 
religion, education). 
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information about how the potential health benefits are 
spread, to better support decision making. The evaluation of 
vaccines or different vaccination programs would be an even 
more important issue during the COVID-19 pandemic. Abbas 
et al. [34] assessed the impact on future mortality with vacci-
nation clinics closed in Africa during lockdown and recom-
mended that the routine children immunization should be 
sustained in Africa as much as possible. It is likely that the 
impact of these suspended vaccination programs, not only on 
health inequality, would be a focus of the future evaluations in 
LMICs.
Policy relevant population subgroups were those differing 
in socioeconomic status. Wealth quintiles were most often 
constructed using household asset indices, which have been 
widely used in literature to create wealth rankings and sepa-
rate the rich from the poor for analyses [35]. Generally, 
a household with better socioeconomic status is expected to 
spend more and possess more of the goods which are con-
sidered essential at a household level. However, the compo-
nents of the asset index are to some degree related to the 
household’s preferences [36], which may not fully reflect the 
socioeconomic status. The asset indices also appear to have 
low internal validity when used in rural areas, thus making 
rural asset holders look poorer than they should and exagger-
ating the urban-rural differences [35]. Income level could be 
an alternative to define household socioeconomic status, as 
did in two of the included studies, but this requires high 
quality of data, which may be difficult in most LMICs. 
Respondents may have difficulty in remembering the exact 
income especially when there are several sources of income in 
the household; respondents might be unaware of the income 
of all household members [37,38]; income might not be stable 
during a period of time as the sources may depend on seaso-
nal effects, e.g. farming and fishing. In view of these draw-
backs, caution should be exercised when asset index or 
income level is used to categorize population subgroups rele-
vant to equity concerns. The associated ambiguity may also 
make it challenging to describe the current level of health 
inequality between these subgroups and further weaken the 
value of estimates of distributional effects of the intervention. 
Region has been used in several studies to characterize policy 
relevant subgroups. Considering the remarkable differences 
Table 3. Outcomes and methods used in the included studies for estimating the distributional effect.
Authors (year)
Methodological framework Summary of inequality 
impact Main results NotesECEA DCEA MCDA Other
Hutton et al. (2010) [24] Subgroup analysis Catch-up vaccination is cost-saving: it increases 
QALYs and saves costs compared to the status 
quo.
Rheingans et al. (2014) [30] Subgroup analysis Rotavirus vaccines are most cost-effective for the 
poor living in high mortality regions. 
Reductions 
in disparities could prevent additional deaths.
Verguet et al. (2015) [15] X The health gains would accrue primarily to the 
poor.
Case study
Campos et al. (2017) [27] Health disparity; 
distributional equity
A policy focusing on increasing HPV screening 
coverage appears to be more compatible with 
improving both 
equity and efficiency than a focus on 
increasing frequency.
Rheingans et al. (2018) [31] Subgroup analysis Children in the poorest households would 
benefit more from the vaccination programme 
than the richest.
Rheingans et al. (2018) [32] Subgroup analysis Rotavirus vaccination could promote health 
equity.
Dawkins et al. (2018) [17] X Equally distributed 
equivalent (EDE) 
health
Prioritizing rural populations can thus be seen as 
being equitable.
Case study
Chang et al. (2018) [29] Subgroup analysis The poorest quintiles would gain the most from 
vaccine programs because they have the most 
to gain, in both  
health and economic terms.
Hangoma et al. (2019) [28] Subgroup analysis A sugar tax in an LMIC context like Zambia 
would improve health outcomes. 
Improvements in health outcomes  
are stronger in women.
Arnold et al. (2020) [18] X Equally distributed 
equivalent (EDE) 
health
Efforts to improve access to the EHP could be 
targeted to specific interventions to improve 
the health of the  
poorest fastest but that identifying these 
interventions is uncertain.
Case study
Love-Koh et al. (2021) [25] X Equally distributed 
equivalent (EDE) 
health
The intervention is likely to be cost-effective but 
that the inequality impacts are small and 
highly uncertain.
Case study
Olsen et al. (2021) [26] Gini index Prioritizing the intervention scale-up in the 
regions with the highest baseline U5MRs 
would reduce geographical inequalities in life 
expectancy.
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between regions such as economic development level, popu-
lation age structure and disease prevalence, it makes sense to 
think about region-related inequality as the potential inter-
vention may be expected to achieve more benefits if it is firstly 
implemented in regions with higher risks and more disadvan-
taged. The results would inform policy makers of which 
regions to prioritize when considering intervention implemen-
tation. However, the focus on area-specific inequalities may 
add uncertainty to the estimation of the intervention impact. 
The newly developed method DCEA [16] accounts for the fact 
that health expenditures would fall proportionally among 
population subgroups and favors the more disadvantaged. 
There is a lack of knowledge about how residents in different 
regions benefit from the health expenditures. Without such 
information, analysts have to make some assumptions, e.g. 
equal distribution, to enable the estimates of distributional 
effect, which may lead to over-/under-estimation of the health 
benefits from an intervention.
To describe the different impacts of health interventions across 
population, reporting results by subgroups is the most straightfor-
ward way. Although there are new methods available, the knowl-
edge and application of these methods is not yet widespread in 
LMICs. This is most likely due to the lack of familiarity with these 
methods. Another obstacle to the application may be the unavail-
ability of existing evidence in LMICs such as preference weights for 
health benefits of different subgroups. The evidence is required to 
aggregate the subgroup cost-effectiveness results into a single 
measure such as EDE health. Possible due to the unavailability, 
analysts prefer to present the results separately for each subgroup 
to describe the impact qualitatively rather than explicitly quantify 
it with some assumptions.
4.2. Recommendations
As previously discussed, the measures, such as asset index and 
income level, used to define equity relevant population sub-
groups may have limitations, and thus a stable, well-constructed 
and multidimensional measure might be preferred in LMICs. For 
example, an index of multiple deprivation is used in England 
which combines information from seven domains to produce an 
overall measure of deprivation [39]. It might be worth exploring 
the feasibility of developing a similar measure suitable in the 
LMIC settings. The availability of such measure would enable 
more research into the role of socioeconomic status on people’s 
health and the distribution of health expenditures. All of these 
would contribute to the development and application of the 
methods assessing intervention impact on inequality in LMICs, 
to support evidence-based decisions.
Regarding the methods used to incorporate inequality 
impact in economic evaluations, we recommend the ECEA 
and DCEA methods to analysts and decision makers in LMICs 
who are interested in conducting an in-depth analysis of the 
intervention impacts on overall health and health inequality. 
Both ECEA and DCEA fundamentally build on standard CEA 
and extend the analysis to describe the distribution of health 
benefits by applying the social inequality aversion preference 
after estimating the costs and benefits for each subgroup 
(using the corresponding parameters). Previous applications 
have shown that the skills required lie within the capabilities 
of analysts currently conducting CEA and the information 
generated could provide decision makers with evidence that 
will enable them to think about equity issues in a more sys-
tematic and science-informed way [16,33,40]. If the decision 
makers are also interested in developing equity ‘benchmarks’ 
to compare across interventions or policy choices, DCEA, 
which uses one single measure to show the trade-offs 
between equity and cost-effectiveness, can be particularly 
useful as a way to understand the impact of policy decisions 
and facilitate transparency and consistency of decision 
making.
Looking ahead, it is expected that there would be more 
applied economic evaluation studies using these new meth-
ods to describe the distribution of health benefits and thus 
inform policy makers with equity concerns in the LMIC setting. 
This requires evidence related to fundamental methodological 
issues such as current level of inequality between policy rele-
vant groups and people’s preferences toward reducing 
inequalities compared to improving health, which might be 
the directions of future research.
5. Conclusions
This systematic review of economic evaluation studies of 
health interventions or strategies in LMICs shows that the 
intervention’s impact on inequality has been considered to 
inform policy makers with equity concerns, and that the 
evaluation studies mainly focused on interventions for the 
more vulnerable groups such as children and women. Two- 
thirds of the included studies were published within the last 
3 years (2018–2020), suggesting an increasing trend to take 
inequality impact into account. Population subgroups were 
mainly defined by wealth quintiles or regions, which could 
reflect policy makers’ preference toward reducing inequal-
ities resulted from socioeconomic status or geographic var-
iations. In terms of the methods used to evaluate the 
inequality impact, most studies reported the cost- 
effectiveness results for population subgroups, and the 
newly developed methods, ECEA and DCEA, have also 
been applied in some studies, demonstrating the usefulness 
and advantages in the provision of scientific evidence. We 
expect that along with increasing capacity and experience 
in the LMIC setting, these methods would be more widely 
used to describe the distribution of health benefits and thus 
guide public health decisions, contributing to the develop-
ment of stronger and more resilient health systems.
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